Petra Lutterbuese

414 total citations
12 papers, 330 citations indexed

About

Petra Lutterbuese is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Petra Lutterbuese has authored 12 papers receiving a total of 330 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Radiology, Nuclear Medicine and Imaging, 9 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Petra Lutterbuese's work include Monoclonal and Polyclonal Antibodies Research (12 papers), CAR-T cell therapy research (7 papers) and Glycosylation and Glycoproteins Research (3 papers). Petra Lutterbuese is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), CAR-T cell therapy research (7 papers) and Glycosylation and Glycoproteins Research (3 papers). Petra Lutterbuese collaborates with scholars based in Germany, Switzerland and United States. Petra Lutterbuese's co-authors include Patrick A. Baeuerle, Peter Kufer, Bernd Schlereth, Scott A. Hammond, Maria Amann, Ralf Lutterbuese, Steve Coats, Roman Kischel, Kathy Mulgrew and Michael D. Oberst and has published in prestigious journals such as Cancer Research, Molecular Cancer Therapeutics and Cancer Immunology Immunotherapy.

In The Last Decade

Petra Lutterbuese

11 papers receiving 310 citations

Peers

Petra Lutterbuese

ONCOL

RNMI

IMMUN

Stacy Fuhrmann United States

Alexandra Huhalov United States

Jacqueline Mock Switzerland

Nina Eißler Sweden

Eun-Sil Sung South Korea

Elmer Santos United States

Gilda Rossoni Italy

Emily Piccione United States

Brian W. Raden United States

Katharina Wartha Switzerland

Stacy Fuhrmann United States

Petra Lutterbuese

206 ×0.9

ONCOL

80 ×0.4

RNMI

158 ×1.2

IMMUN

127 ×1.2

26 ×1.0

Citations per year, relative to Petra Lutterbuese Petra Lutterbuese (= 1×) peers Stacy Fuhrmann

Countries citing papers authored by Petra Lutterbuese

Since Specialization

Citations

This map shows the geographic impact of Petra Lutterbuese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petra Lutterbuese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petra Lutterbuese more than expected).

Fields of papers citing papers by Petra Lutterbuese

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Petra Lutterbuese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petra Lutterbuese. The network helps show where Petra Lutterbuese may publish in the future.

Co-authorship network of co-authors of Petra Lutterbuese

This figure shows the co-authorship network connecting the top 25 collaborators of Petra Lutterbuese. A scholar is included among the top collaborators of Petra Lutterbuese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petra Lutterbuese. Petra Lutterbuese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Lutterbuese, Petra, Matthias G. Friedrich, Famke Aeffner, et al.. (2025). How useful are 3-month repeat-dose toxicology studies for the development of T cell engagers for oncology indications?. Regulatory Toxicology and Pharmacology. 162. 105859–105859.

Pham, Elizabeth, Petra Lutterbuese, Petra Deegen, et al.. (2023). Abstract ND06: AMG 305, a dual targeting BiTE®molecule with selective activity for solid tumors that co-express CDH3 and MSLN. Cancer Research. 83(7_Supplement). ND06–ND06. 7 indexed citations

Bailis, Julie M., Petra Lutterbuese, Oliver S. Thomas, et al.. (2020). Abstract 3364: Preclinical evaluation of BiTE®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer. Cancer Research. 80(16_Supplement). 3364–3364. 8 indexed citations

Oberst, Michael D., Stacy Fuhrmann, Kathy Mulgrew, et al.. (2014). CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. mAbs. 6(6). 1571–1584. 71 indexed citations

Fuhrmann, Stacy, Maria Amann, Kathy Mulgrew, et al.. (2010). Abstract 5625: In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody in development for the treatment of gastrointestinal adenocarcinomas. Cancer Research. 70(8_Supplement). 5625–5625. 1 indexed citations

Lutterbuese, Ralf, Tobias Raum, Roman Kischel, et al.. (2009). Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA. Journal of Immunotherapy. 32(4). 341–352. 64 indexed citations

Mulgrew, Kathy, David J. Stewart, Wendy L. Trigona, et al.. (2008). Bioavailability, pharmacodynamic activity, and anti-tumor efficacy of the CD19/CD3-specific BiTE antibody MEDI-538 (MT103) delivered subcutaneously in animal models. Cancer Research. 68. 2131–2131. 2 indexed citations

Amann, Maria, Matthias Friedrich, Petra Lutterbuese, et al.. (2008). Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. Cancer Immunology Immunotherapy. 58(1). 95–109. 30 indexed citations

Amann, Maria, Klaus Brischwein, Petra Lutterbuese, et al.. (2008). Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3. Cancer Research. 68(1). 143–151. 68 indexed citations

10.

Hammond, Scott A., Ralf Lutterbuese, Shannon Roff, et al.. (2007). Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct. Cancer Research. 67(8). 3927–3935. 66 indexed citations

11.

Baeuerle, Patrick A., Maria Amann, Klaus Brischwein, et al.. (2007). Therapeutic window of MuS110, a single-chain antibody construct bispecific for EpCAM (CD326) and CD3. Molecular Cancer Therapeutics. 6. 3 indexed citations

12.

Lutterbuese, Petra, Klaus Brischwein, Robert Hofmeister, et al.. (2006). Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunology Immunotherapy. 56(4). 459–468. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact